Exact Sciences Corporation raised revenue guidance for the full year 2023. For the period, the company expects revenue to be in the range of $2.476 billion - $2.486 billion, assuming: Screening revenue of $1.848 billion - $1.853 billion, precision Oncology revenue of $622 million - $627 million, and COVID-19 testing revenue of $6 million compared to previous revenue guidance of $2.441 billion - $2.466 billion, which assumed screening revenue of $1.820 billion - $1.835 billion, precision Oncology revenue of $615 million - $625 million, and COVID-19 testing revenue of $6 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
53.49 USD | -0.06% | +0.28% | -27.70% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.70% | 9.87B | |
+27.06% | 2.89B | |
-16.78% | 2.75B | |
-15.31% | 2.13B | |
-21.41% | 1.65B | |
+68.70% | 1.47B | |
+29.75% | 811M | |
-5.02% | 733M | |
-29.39% | 510M | |
+1.59% | 300M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Raises Revenue Guidance for the Full Year 2023